Document is current
Any future updates will be listed below
-
Authors
,
Newman, Kira L. http://orcid.org/0000-0002-8279-1111
Rogers, Julia H.
McCulloch, Denise
Wilcox, Naomi
Englund, Janet A.
Boeckh, Michael
Uyeki, Timothy M.
Jackson, Michael L.
Starita, Lea
Hughes, James P.
Chu, Helen Y.
-
Funding
Funding for this research was provided by:
Gates Ventures (Seattle Flu Study)
- License Information
-
More Information
Article History
Received: 14 June 2020
Accepted: 4 November 2020
First Online: 23 November 2020
Ethics approval and consent to participate
: The project has been approved by the Institutional Review Board (IRB) at the University of Washington. This trial will be conducted according to Good Clinical Practice (GCP) guidelines appropriate for use of FDA-approved medications.Consent and assent, as appropriate, will be obtained from all participants. All participants will be reminded that involvement in research is always optional, and they may terminate their participation at any time without consequences. Neither shelter staff nor the study funder will have access to an individual participant’s data or test results.
: Not applicable.
: JAE: Consulting fees from Sanofi Pasteur and Meissa Vaccines; research support from AstraZeneca, GlaxoSmithKline, Novavax, and Merck. MB: Consulting fees and research support from Gilead Sciences, Janssen, Ansun Biopharma, GlaxoSmithKline, Vir Biotechnology; consulting fees from Pulmocyte, Adma Biologics, Moderna, Evrys Bio; research support from Alveo. MLJ: research funding from Sanofi Pasteur. HYC: Consulting fees from Merck and Glaxo Smith Kline, and research support from Sanofi Pasteur, Ellume, Genentech, and Cepheid. All other authors report no competing interests.
